$2.0bn
$XXX.Xm
28
350
$X.Xbn
Intravenous (IV) solution manufacturers supply hospitals and healthcare facilities with essential IV products. The steady growth in hospital demand and the crucial nature of medical treatments have provided some safeguards against economic downturns. In 2020, when faced with COVID-19 restrictions, industry revenue increased as most hospitalized patients needed IV products. But rising plastic materials and resin costs paired with a decline in overall health expenditure have curbed growth rates. As a result, industry-wide revenue has grown at a modest CAGR of 0.2% to $2.0 billion over the five years to 2023, including a 3.6% bounce back in revenue in 2023 alone.The IV solutions market is concentrated, with more than three-quarters of total revenue generated by the sector's three largest manufacturers (Baxter International Inc., ICU Medical Inc. and B. Braun Medical Inc). Merger and acquisition activities have bolstered vertical integration and helped protect industry profit from escalating purchase costs. As these corporations expand their output and grow vertically, taking over more parts of their supply chain, the per-unit production costs drop and cost savings can be passed to wholesalers, hospitals and healthcare clinics as lower prices.The price control exerted by the industry's leaders has restricted the entry of new producers, but entering niche markets remains economically viable as excess demand and supply shortages occur. In the future, market growth is expected to surpass previous records with the rise in the median age of the US population, continued export growth and strong demand from hospitals driving this surge. Insurance and government programs that fund healthcare will also support growth. Although there are substitutes for IV products, cost savings from production innovations (e.g. robotics and automation) reduce wages and input costs while providing equal or improved quality allowing manufacturers flexibility to adjust pricing to match competitor products' prices. With the number of establishments increasing and prominent manufacturers transforming production, industry revenue is forecast to grow at a more robust CAGR of 3.0% to $2.3 billion over the five years to 2028.
Industry revenue has grown at a CAGR of 0.2 % over the past five years, to reach an estimated $2.0bn in 2023.
Market size is projected to grow over the next five years.
Company | Market Share (%)
2023 | Revenue ($m)
2023 | Profit ($m)
2023 | Profit Margin (%)
2023 |
---|---|---|---|---|
Baxter International Inc. | 643.2 | 72.7 | 11.3 | |
B. Braun Medical Inc. | 516.4 | 27.6 | 5.3 | |
Icu Medical, Inc. | 241.2 | 12.4 | 5.1 |
To view the market share and analysis for all 3 top companies in this industry, view purchase options.
Intravenous (IV) Solution Manufacturing in the US
Industry revenue is measured across several distinct product and services lines, including Crystalloids, Colloids and Blood products. Crystalloids is the largest segment of the Intravenous (IV) Solution Manufacturing in the US.
Crystalloids purchases infuse manufacturers with more revenue
Companies in this industry primarily engage in manufacturing substances that may be infused directly into a vein using a venous access device. Intravenous (IV) solutions may be used to correct electrolyte imbalances, to deliver medications, for blood transfusion or as fluid replacement. Solutions specifically for animals are excluded from this industry.
Purchase this report to view all 3 major companies in this industry.
NAICS 32541 - Intravenous (IV) Solution Manufacturing in the US
Get an indication of the industry's health through historical, current and forward-looking trends in the performance indicators that make or break businesses.
The need for IV solutions products surges with an aging population. The growing need for healthcare services among older Americans, driven by medical advancements and heighte...
Learn about an industry's products and services, markets and trends in international trade.
Hospital attendance bolsters orders for intravenous (IV) solutions. Hospitals are the largest market for IV solutions since the product is widely used for various procedures ...
Discover where business activity is most concentrated in an industry and the factors driving these trends to find opportunities and conduct regional benchmarking.
Freight costs foster a mildly fragmented market. The cost of transporting prepared intravenous (IV) solutions has been an important variable in explaining the existence of a ...
Get data and insights on what's driving competition in an industry and the challenges industry operators and new entrants may face, with analysis built around Porter's Five Forces framework.
More prominent manufacturers will continue to dominate the market. Market concentration is increasing, and manufacturers are expanding capacity and enhancing supply reliabili...
Learn about the performance of the top companies in the industry.
B. Braun Medical has a brawny market share. Braun Medical is considered a disruptor with an increasing share but weaker profit than market peers.
Understand the demographic, economic and regulatory factors that shape how businesses in an industry perform.
Natural disasters highlight supply chain vulnerability. In 2017, Hurricane Maria highlighted the vulnerability of the US IV solution supply and the importance of the governme...
View average costs for industry operators and compare financial data against an industry's financial benchmarks over time.
Buyers' purchasing power can influence market price. Substitute products and buyers' participation in group purchasing organizations reduce manufacturers' pricing discretion.
Including values and annual change:
IBISWorld has been a leading provider of trusted industry research for over 50 years to the most successful companies worldwide. With offices in Australia, the United States, the United Kingdom, Germany and China, we are proud to have local teams of analysts that conduct research, data analysis and forecasting to produce data-driven industry reports.
Our analysts start with official, verified and publicly available sources of data to build the most accurate picture of each industry. Analysts then leverage their expertise and knowledge of the local markets to synthesize trends into digestible content for IBISWorld readers. Finally, each report is reviewed by one of IBISWorld’s editors, who provide quality assurance to ensure accuracy and readability.
IBISWorld relies on human-verified data and human-written analysis to compile each standard industry report. We do not use generative AI tools to write insights, although members can choose to leverage AI-based tools within the platform to generate additional analysis formats.
Each industry report incorporates data and research from government databases, industry-specific sources, industry contacts, and our own proprietary database of statistics and analysis to provide balanced, independent and accurate insights.
Key data sources in the US include:
Analysts also use industry specific sources to complement catch-all sources, although their perspective may focus on a particular organization or representative body, rather than a clear overview of all industry operations. However, when balanced against other perspectives, industry-specific sources provide insights into industry trends.
These sources include:
Finally, IBISWorld’s global data scientists maintain a proprietary database of macroeconomic and demand drivers, which our analysts use to help inform industry data and trends. They also maintain a database of statistics and analysis on thousands of industries, which has been built over our more than 50-year history and offers comprehensive insights into long-term trends.
IBISWorld’s analysts and data scientists use the sources above to create forecasts for our proprietary datasets and industry statistics. Depending on the dataset, they may use regression analysis, multivariate analysis, time-series analysis or exponential smoothing techniques to project future data for the industry or driver. Additionally, analysts will leverage their local knowledge of industry operating and regulatory conditions to impart their best judgment on the forecast model.
IBISWorld prides itself on being a trusted, independent source of data, with over 50 years of experience building and maintaining rich datasets and forecasting tools. We are proud to be the keystone source of industry information for thousands of companies across the world.
Learn more about our methodology and data sourcing on the Help Center.
Unlock comprehensive answers and precise data upon purchase. View purchase options.
The market size of the Intravenous (IV) Solution Manufacturing in the US industry in United States is $2.0bn in 2024.
There are 350 businesses in the Intravenous (IV) Solution Manufacturing in the US industry in United States, which has grown at a CAGR of 4.0 % between 2018 and 2023.
The market size of the Intravenous (IV) Solution Manufacturing in the US industry in United States has been growing at a CAGR of 0.2 % between 2018 and 2023.
Over the next five years, the Intravenous (IV) Solution Manufacturing in the US industry in United States is expected to grow.
The biggest companies operating in the Intravenous (IV) Solution Manufacturing market in United States are Baxter International Inc., B. Braun Medical Inc. and Icu Medical, Inc.
Crystalloids and Colloids are part of the Intravenous (IV) Solution Manufacturing in the US industry.
The company holding the most market share in United States is Baxter International Inc..
The level of competition is moderate and steady in the Intravenous (IV) Solution Manufacturing in the US industry in United States.